EUVIMEDEUVIMED entdecken
Crossref

A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer

Chaoli An, Xuefeng Qiu, Beibei Liu, Xiang Song, Yu Yang, Jiaxin Shu, Yao Fu, Feng Wang, Xiaozhi Zhao, Hongqian Guo

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-04947-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, 2024. Verfasst von Chaoli An und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: the Sino-German Mobility Programme (M-0670), the Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study is to investigate the diagnostic value of 68Ga-PSMA-11 in improving the concordance between mpMRI-TB and combined biopsy (CB) in detecting PCa. METHODS: 115 consecutive men with 68Ga-PSMA-11 PET/CT prior to prostate biopsy were included for analysis. PSMA intensity, quantified as maximum standard uptake value (SUVmax), minimum apparent diffusion coefficient (ADCmin) and other clinical characteristics were evaluated relative to biopsy concordance using univariate and multivariate logistic regression analyses. A prediction model was developed based on the identified parameters, and a dynamic online diagnostic nomogram was constructed, with its discrimination evaluated through the area under the ROC curve (AUC) and consistency assessed using calibration plots. To assess its clinical applicability, a decision curve analysis (DCA) was performed, while internal validation was conducted using bootstrapping methods. RESULTS: Concordance between mpMRI-TB and CB occurred in 76.5% (88/115) of the patients. Multivariate logistic regression analyses performed that SUVmax (OR= 0.952; 95% CI 0.917-0.988; P= 0.010) and ADCmin (OR= 1.006; 95% CI 1.003-1.010; P= 0.001) were independent risk factors for biopsy concordance. The developed model showed a sensitivity, specificity, accuracy and AUC of 0.67, 0.78, 0.81 and 0.78 in the full sample. The calibration curve demonstrated that the nomogram's predicted outcomes closely resembled the ideal curve, indicating consistency between predicted and actual outcomes. Furthermore, the decision curve analysis (DCA) highlighted the clinical net benefit achievable across various risk thresholds. These findings were reinforced by internal validation. CONCLUSIONS: The developed prediction model based on SUVmax and ADCmin showed practical value in guiding the optimization of prostate biopsy pattern. Lower SUVmax and Higher ADCmin values are associated with greater confidence in implementing mono-TB and safely avoiding SB, effectively balancing benefits and risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedHumansMaleBiopsyGallium IsotopesGallium RadioisotopesImage-Guided BiopsyNomogramsPredictive Value of TestsProstateRetrospective StudiesRisk Assessment

Stichwörter der Autor:innen

ADCminBiopsy concordancePSMA PET/CTProstate cancerSUVmaxTargeted biopsy

Substanzen

Gallium IsotopesGallium Radioisotopesgallium 68 PSMA-11

Autor:innen und Institutionen

  • Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
  • Department of Andrology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
  • Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, China.
  • Department of Pathology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China.
  • Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210003, China. fengwangcn@hotmail.com.
  • Department of Andrology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China. dr.zxz@hotmail.com.

Förderung

  • the Sino-German Mobility Programme (M-0670), the Natural Science Foundation of Jiangsu Province

Zitieren

APA

An, C., Qiu, X., Liu, B., Song, X., Yang, Y., Shu, J., Fu, Y., Wang, F., Zhao, X., & Guo, H. (2024). A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer. World Journal of Urology. https://doi.org/10.1007/s00345-024-04947-w

Vancouver

An C, Qiu X, Liu B, Song X, Yang Y, Shu J, et al. A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer. World Journal of Urology. 2024. doi:10.1007/s00345-024-04947-w

BibTeX
@article{An2024,
  author = {An, Chaoli and Qiu, Xuefeng and Liu, Beibei and Song, Xiang and Yang, Yu and Shu, Jiaxin and Fu, Yao and Wang, Feng and Zhao, Xiaozhi and Guo, Hongqian},
  title = {A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-04947-w}
}
Kostenlos starten →